What is the most recent earnings date for PYXS stock?
PYXIS ONCOLOGY INC (PYXS) last reported earnings on 11/3/2025.
NASDAQ:PYXS • US7473241013
Past quarterly earnings results for PYXIS ONCOLOGY INC (PYXS), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | -0.35 | -0.35 | -1.35% | - | - | - | ||
| Q2 2025 | -0.30 | -0.36 | 16.37% | -3.45% | 2.82M | - | - | |
| Q1 2025 | -0.35 | -0.30 | -16.71% | -483.33% | - | -100.00% | ||
| Q4 2024 | -0.25 | -0.34 | 25.73% | 24.24% | - | - | ||
| Q3 2024 | -0.35 | -0.32 | -9.51% | 37.50% | - | - | ||
| Q2 2024 | -0.29 | -0.33 | 12.33% | 29.27% | - | - | ||
| Q1 2024 | -0.06 | -0.25 | 75.69% | 89.09% | 16.146M | 4.208M | 283.70% | - |
| Q4 2023 | -0.33 | -0.48 | 31.89% | 67.33% | 170.003K | -100.00% | - | |
| Q3 2023 | -0.56 | -0.52 | -8.36% | 34.12% | - | - | ||
| Q2 2023 | -0.41 | -0.66 | 37.92% | 48.10% | 637.5K | -100.00% | - | |
| Q1 2023 | -0.55 | -0.92 | 39.97% | 43.30% | - | - | ||
| Q4 2022 | -1.01 | -0.95 | -6.56% | 48.99% | - | - | ||
| Q3 2022 | -0.85 | -0.83 | -2.44% | 90.51% | - | - | ||
| Q2 2022 | -0.79 | -0.78 | -1.64% | - | - | - | ||
| Q1 2022 | -0.97 | -0.62 | -56.03% | - | - | - | ||
| Q4 2021 | -1.98 | -0.37 | -431.47% | - | - | - | ||
| Q3 2021 | -8.96 | -0.52 | -1,618.20% | - | - | - | ||
| Q2 2021 | - | - | - | - | ||||
| Q1 2021 | - | - | - | - | ||||
| Q4 2020 | - | - | - | - | ||||
| Q3 2020 | - | - | - | - | ||||
| Q2 2020 | - | - | - | - |
Notes
PYXIS ONCOLOGY INC (PYXS) last reported earnings on 11/3/2025.
PYXIS ONCOLOGY INC (PYXS) missed EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, PYXIS ONCOLOGY INC (PYXS) has beaten EPS estimates in 2 out of 4 releases.